Advertisement

Topics

GTx Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results

16:05 EDT 12 Mar 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
-- Enobosarm for Stress Urinary Incontinence (SUI) continues to show sustained durability of response in Phase 2 proof of concept clinical trial -- -- Top-line results from the ASTRID trial, a Phase 2 placebo-con...

Other Sources for this Article

GTx, Inc.
Investors:
Argot Partners
Kimberly Minarovich or Sam Martin
212-600-1902
or
Media:
Red House Consulting
Denise Powell, 510-703-9491
denise@redhousecomms.com

NEXT ARTICLE

More From BioPortfolio on "GTx Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Stress
Stress is caused by your perception of situations around you and then the reaction of your body to them. The automatic stress response to unexpected events is known as 'fight or flight'. Discovered by Walter Cannon in 1932, it is the release of h...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...